Physician profile
Benjamin Bashline
NPI 1982947966
$9,572.91
in general payments reported to CMS, 2019-2025
37 companies · $2,905 in 2025
The $2,905 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $300 · 2021: $764 · 2022: $852 · 2023: $1,432 · 2024: $2,644 · 2025: $2,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,507 · Education: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,507.11 |
| Education | $473.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.83 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,231.72 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $1,130.60 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $874.41 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $601.66 | 2019-2025 | Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $562.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $538.66 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $497.15 | 2019-2025 | |
| Amgen INC. | $384.87 | 2020-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $355.42 | 2021-2024 | Tremfya |
| Leo Pharma INC. | $333.28 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $314.54 | 2023-2025 | Opzelura |
| Pfizer INC. | $259.41 | 2019-2025 | |
| Galderma Laboratories, L.P. | $156.33 | 2019-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.62 | 2022-2024 | Spevigo |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Bashline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.